Generic Central Nervous System Drugs Market New Trends, Growth Opportunities, Top Players And Forecast To 2033

The generic central nervous system drugs market size has grown strongly in recent years. It will grow from $83.71 billion in 2023 to $89.47 billion in 2024 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to from increasing number of surgeries, strong growth in emerging markets, and increase in pharmaceutical r&d, geriatric population and increased healthcare expenditure.

The generic central nervous system drugs market size is expected to see strong growth in the next few years. It will grow to $117.21 billion in 2028 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to growing government initiatives for mental health awareness, rise in healthcare expenditure, increasing geriatric population and strong pipeline of drugs. Major trends in the forecast period include invest in wearable technology, biomarkers in cns development, modify existing drugs, invest in drug pipeline, use of 3d printing for drug manufacturing and focus on establishing collaborations with research institutions and established companies. player-adopted strategies in the central nervous system drugs market includes acquiring emerging technological companies, expanding brand portfolios through new product launches and expanding business operations in other regions.

Market Overview -
Generic central nervous system (CNS) drugs refer to the drugs that have an impact on the central nervous system agents (CNS) by slowing down brain activity. They are used to treat seizures, anxiety, panic attacks, and insomnia.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=9315&type=smp

Rising Incidence Of Mental Health Disorders Fuels Growth In The Generic Central Nervous System (CNS) Drug Market
The increasing incidence of mental health disorders is expected to propel the growth of the generic central nervous system (CNS) drug market going forward. A mental health disorder is a clinically substantial impairment in a person's cognition, emotional regulation, or conduct. It is usually linked to distress or functional impairment in key areas. Generic central nervous system (CNS) drugs play a crucial role in the management of mental health disorders by providing affordable and accessible treatment options. For instance, in November 2022, according to the Health and Social Care Information Centre, a UK-based federal body that offers content, data, and computer systems for experts, physicians, and controllers in the social and healthcare sectors, the proportion of 17- to 19-year-olds with a suspected mental disorder grew from 17.4% in 2021 to 25.7% in 2022. Therefore, the increasing incidence of mental health disorders is driving the generic central nervous system (CNS) drug market.

Competitive Landscape -
Major companies operating in the generic central nervous system drugs market report are Biogen Inc., Johnson & Johnson, Hoffmann-La Roche Ltd, Novartis AG, UCB, Sanofi, Pfizer Inc., Merck KGaA, Sumitomo Dainippon Pharma, AbbVie, Recipharm AB, Neuraxpharm, Sun Pharmaceutical limited, Ranbaxy Laboratories, Merz Pharma GmbH & Co. KGaAare, AstraZeneca, Apotex, Gilead Sciences, Bayer, GlaxoSmithKline, Amgen, Abbott Laboratories, Janssen Pharmaceutica, Teva Canada, Accord Healthcare Inc., Acerus Pharmaceuticals Corporation, Amgen, EMS Pharma, Hypermarcas, Eurofarma, Teuto Brasileiro, Biolab Farmaceutica, Cristalia, União Quimica, Boehringer Ingelheim, Eli Lilly and Company, Adcock Ingram

Innovative Solutions Drive Growth In Generic Central Nervous System Drugs Market
Product innovations have emerged as a key trend gaining popularity in the generic central nervous system drugs market. Major companies operating in the generic central nervous system drugs market are focused on developing innovative products and solutions to strengthen their position in the market. For instance, in December 2021, Intra-Cellular Therapies, Inc. a US-based biopharmaceutical company launched CAPLYTA for the treatment of depressive episodes associated with bipolar I or II disorder in adults, as monotherapy and as adjunctive therapy with lithium or valproate. As a monotherapy or adjunctive therapy with lithium or valproate, CAPLYTA is the only medication approved by the FDA to treat depressive disorders associated with bipolar I or bipolar II. When it comes to weight, cardiometabolic parameters, and extrapyramidal symptoms (disturbances in movement), CAPLYTA has consistently demonstrated a positive profile. Approximately 11 million adults in the United States suffer from bipolar I and bipolar II disorder, serious, highly prevalent mental health conditions marked by recurrent episodes of mania or hypomania interspersed with periods of major depression (bipolar depression). About half of all bipolar disorder patients have either bipolar I disorder or bipolar II disorder.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/generic-central-nervous-system-drugs-global-market-report

Key Segments -
The generic central nervous system drugs market covered in this report is segmented -
1) By Type: Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other Types
2) By Drug Classification: Branded Drugs, Generic Drugs
3) By Disease: Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer
4) By Route Of Administration: Oral, Intravenous, Intranasal/ Inhalation, Other Route Of Administrations
5) By Mode Of Purchase: Over-the-counter drugs, Prescription-Based Drugs
6) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.